Introduction: This analysis was conducted to assess the tolerability, safety, and efficacy of brivaracetam (BRV) for adjunctive treatment of focal (partial-onset) seizures in patients aged ≥65 years. Methods: Safety/tolerability and efficacy data for patients aged ≥65 years were pooled from three randomized, double-blind, placebo-controlled, fixed-dose Phase III studies (NCT00490035, NCT00464269, and NCT01261325). Data were pooled by treatment group: placebo or the proposed therapeutic dose range of 50-200 mg/day: BRV 50, 100, 200 mg/day. Results: Thirty-two patients aged ≥65 years were randomized to placebo or BRV 50-200 mg/day. Of these, 30 patients (93.8%) completed their respective study. In the safety population (n = 32), 87.5% placebo-vs 73.3% BRV-treated patients reported treatment-emergent adverse events (TEAEs) during the treatment period; most commonly, headache (25.0% vs 12.5%), paresthesia (0% vs 12.5%), and somnolence (50.0% vs 12.5%) for placebo-vs BRV-treated patients, respectively. During the treatment period, drug-related TEAEs were reported by 62.5% of placebo-vs 53.3% of BRV-treated patients, and serious TEAEs (SAEs) were reported by 0% of placebo-and 4.2% of BRV-treated patients; there were no drug-related SAEs and no deaths. Three SAEs (placebo 1/8; BRV 2/24) and two deaths (placebo 1/8; BRV 1/24) occurred in the post-treatment period. In the efficacy population (n = 31), median percent reduction from baseline in focal seizure frequency/28 days was 14.0% for placebo vs 25.5%, 49.6%, and 74.9% for BRV 50, 100, and 200 mg/day, respectively. The ≥50% responder rate was 14.3% for placebo vs 25.0%, 50.0%, and 66.7% for BRV 50, 100, and 200 mg/day, respectively. Conclusions: Safety/tolerability and efficacy findings in this small subgroup of older patients treated with adjunctive BRV are consistent with those observed in the much larger overall pooled population. BRV may be a suitable adjunctive treatment for older patients with uncontrolled focal seizures. Further larger studies in this population are warranted.
Introduction
Epilepsy is common in older adults; causes of new-onset epilepsy at older ages include cerebrovascular disease, dementia, Alzheimer's, brain tumor, primary neurodegenerative disorders, and traumatic head injury (Brodie et al., 2009; Pugh et al., 2009 ). The incidence of treated epilepsy has been estimated at 80.8 per 100,000 in the general population, rising to 85.9 per 100,000 in those aged 65-69 years, and 135.4 per 100,000 in people ≥85 years (Wallace et al., 1998) . In addition to older patients with new-onset epilepsy, the population of older adults with epilepsy also includes those who have been treated for many decades.
The mortality rates for people diagnosed with epilepsy are 3.1, 1.7, and 2.0 times greater than the general population for those aged 60-69, 70-79, and ≥80 years (Lhatoo et al., 2001) . Age-associated effects on antiepileptic drug (AED) pharmacokinetics (PK) and pharmacodynamics mean that AED selection and dosages may need adjustment in this population (Turnheim, 2003) . Older patients are often receiving concomitant drugs for multiple comorbidities. Therefore, enzyme induction by some AEDs poses a particular challenge for optimal polypharmacy in older patients (Brodie et al., 2013; Perucca, 2006) .
There are relatively few randomized controlled trials of AEDs in older populations. The evidence base currently supports the use of lamotrigine or levetiracetam (LEV) as a first-line AED in older patients with epilepsy (Brodie et al., 1999; Rowan et al., 2005; Saetre et al., 2007; Werhahn et al., 2015) .
Brivaracetam (BRV), a selective, high-affinity synaptic vesicle protein 2A ligand, has been approved by the USA, Canada, and Europe as adjunctive therapy for focal seizures in adults (≥16 years) with epilepsy. A study in 16 older healthy volunteers found that BRV was well tolerated, with adverse events comparable to a younger population (Sargentini-Maier et al., 2009) . The objective of the current analysis was to assess the tolerability, safety, and efficacy of BRV for adjunctive treatment of focal seizures in older patients. This article reports a post-hoc analysis of pooled data from three pivotal studies which enrolled patients aged ≥65 years (Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 2014) .
Methods

Study designs
The methodology and study designs have been published for the three randomized, double-blind, placebo-controlled, fixed-dose Phase III studies used in this analysis (Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 2014) . After an 8-week prospective baseline period, patients received placebo or BRV (5-200 mg/day), initiated without up-titration for a 12-week treatment period. The studies were conducted in accordance with accepted guidelines and all patients provided written informed consent before study enrolment.
Participants
The three studies enrolled patients with focal seizures, with or without secondary generalization, uncontrolled on 1-2 AEDs. Studies NCT00490035 and NCT00464269 included adults aged 16-70 years ≥45 kg. Study NCT01261325 included adults aged 16-80 years ≥40 kg. Patients were required to have ≥2 focal seizures/month during the 3 months before baseline, and ≥8 focal seizures during the 8-week baseline period (with ≥2 focal seizures during each 4-week period in study NCT01261325). In two studies, concomitant LEV was limited to 20% of the population; in study NCT01261325 concomitant LEV was not allowed.
Endpoints and statistical analysis
Tolerability and safety endpoints were treatment-emergent adverse events (TEAEs), laboratory assessments, vital signs, and electrocardiograms (ECGs) during the treatment period. Efficacy endpoints included median percent reduction in focal seizure frequency from baseline/28 days, ≥50% responder rate (≥50% reduction in focal seizure frequency from baseline), and seizure freedom rate (all seizure types) during the treatment period.
Data from the three studies were pooled; further details are presented elsewhere (Ben-Menachem et al., 2016) . Data were pooled by treatment group for the approved dose range of 50-200 mg/day: BRV 50, 100, 200 mg/day or placebo. This post-hoc analysis included patients aged ≥65 years.
The safety population comprised patients taking ≥1 dose of study drug. The efficacy population comprised patients from the primary efficacy analyses: the intent-to-treat (ITT) population in studies NCT00490035 and NCT01261325, and the modified ITT population in study NCT00464269, who were not receiving LEV at study entry.
Results
Patient disposition
Overall, 1558 patients were randomized, of whom 38 were aged ≥65 years. Of these, 32 patients were randomized to placebo (n = 8) or BRV 50-200 mg/day (n = 24) and are included in the safety population of this analysis. In total, 30/32 patients (93.8%) completed their respective studies; 2/32 (6.3%) discontinued due to adverse events.
Patient demographics and baseline characteristics
At baseline, patients ≥65 years had a mean (standard deviation [SD] ) age of 72.1 (4.2) years vs 69.3 (3.6) years, and 57.1% and 54.2% were male, in the placebo and BRV groups, respectively. Patients had a long duration of epilepsy (mean [SD] duration: 24.8 [14.7] vs 34.1 [20.6] years), and median focal seizure frequency/28 days at baseline was 9.6 vs 7.5, for the placebo and BRV groups, respectively. Most patients had discontinued ≥2 prior AEDs; more than half had previously discontinued LEV. The most common concomitant AEDs were oxcarbazepine, carbamazepine, lamotrigine, and lacosamide (Table 1) .
Safety and tolerability
In patients aged ≥65 years (n = 32), mean (SD) drug exposure was 81.1 (12.0) days for placebo and 82.6 (18.0) days for BRV.
Altogether, 7/8 (87.5%) placebo vs 16/24 (66.7%) BRV patients reported TEAEs during the treatment period (Table 2 ). Of these, 5/8 (62.5%) placebo vs 13/24 (54.2%) BRV patients reported drugrelated TEAEs. Few patients discontinued study drug due to TEAEs: 1/8 (12.5%) patients on placebo and 1/24 (4.2%) patients on 100 mg/day BRV. The most commonly reported TEAEs were headache (placebo 2/8; 25.0% vs BRV 3/24; 12.5%), paresthesia (0/8; 0% vs 3/24; 12.5%), and somnolence (4/8; 50.0% vs 3/24; 12.5%) ( Table 2) .
During the treatment period, serious TEAEs (SAEs) were reported by no placebo patients and one BRV-treated patient (a 76-year-old woman receiving BRV 100 mg/day fell after a seizure resulting in hematoma, kidney injury, and a broken rib; BRV was permanently discontinued). No drug-related SAEs or deaths were reported during the treatment period.
After core study completion, SAEs were reported by one placebo-and two BRV-treated patients. A 70-year-old woman receiving BRV during long-term follow-up fractured her pelvis in an accidental fall (considered unrelated to study drug), which resolved. A 68-year-old man previously receiving placebo died from septicemia and a 70-year-old man previously receiving BRV 100 mg/day had a septic infection (after 8 days the patient went into septic shock, BRV was withdrawn, and after 3 weeks the patient died). Both deaths were thought unlikely related to study drug.
Patient numbers were small; however, there were no trends of clinical concern in the laboratory assessments.
Efficacy
In patients aged ≥65 years (n = 31), median percent reduction from baseline in focal seizure frequency/28 days was 14.0% (placebo) vs 25.5%, 49.6%, and 74.9% (BRV 50, 100, and 200 mg/day, respectively) ( Fig. 1A) . Similarly, the ≥50% responder rate was 1/7 (14.3%) for placebo vs 1/4 (25.0%), 7/14 (50.0%), and 4/6 (66.7%) Note: The efficacy population comprised all patients from the primary efficacy analyses in studies N01252, N01253, and N01358, excluding patients receiving concomitant LEV in studies N01252 and N01253. AED, antiepileptic drug; BMI, body mass index; BRV, brivaracetam; LEV, levetiracetam; SD, standard deviation.
a Other race includes black, other, and missing. b ≥10% in BRV overall group.
Table 2
Summary of TEAEs and most commonly reported TEAEs during the treatment period (n = 32). for BRV 50, 100, and 200 mg/day, respectively (Fig. 1B) . Efficacy appeared to increase with increased BRV dosage, although the patient numbers were small. The number of patients continuously free of seizures (all seizure types) were 0/7 (placebo) vs 3/24 BRV (1/4, 1/14, and 1/6 patients for BRV 50, 100, and 200 mg/day, respectively).
Discussion and conclusions
In this small subgroup of older patients treated with adjunctive BRV, a comprehensive evaluation of TEAEs and laboratory assessments did not reveal any issues of clinical concern. Seizure control rates were higher with BRV than placebo and compared favorably with those observed in the much larger overall pooled population (Ben-Menachem et al., 2016) . Indeed, seizure reduction rates were higher than for the overall population. It should be noted that the population analyzed here had a long epilepsy duration and the majority had received ≥2 prior AEDs; they were therefore not typical of patients with new-onset epilepsy at older ages.
BRV has several characteristics which make it a potentially favorable choice for older patients, although appropriate caution should be taken for this population; a lower dose may be necessary for patients with decreased hepatic, renal, or cardiac function. BRV has a low potential to induce or inhibit the cytochrome (CYP) system , except for CYP2C19 which is involved in secondary metabolism of BRV (Sargentini-Maier et al., 2008) . It acts as a moderate inhibitor of epoxide hydrolase . In the pivotal trials, BRV showed a favorable safety and tolerability profile and titration was not required for tolerability reasons (Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 2014) .
Limitations of this analysis include its post-hoc nature and the small number of patients aged ≥65 years. A higher age cut-off or further age stratifications might be useful in future studies, as might studies in patients with late-onset epilepsy.
Based on these results, BRV may be a suitable adjunctive treatment for older patients with uncontrolled focal seizures. The tolerability and safety profile was similar to, and efficacy rates were higher than, the overall pooled population. However, owing to the small number of patients in this analysis, further studies in older patients are warranted.
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